Clinical and translational advances in ovarian cancer therapy
Publication type: Journal Article
Publication date: 2023-08-31
scimago Q1
wos Q1
SJR: 11.941
CiteScore: 34.2
Impact factor: 28.5
ISSN: 26621347
PubMed ID:
37653142
Cancer Research
Oncology
Abstract
Ovarian cancer is an aggressive disease that is frequently detected at advanced stages and is initially very responsive to platinum-based chemotherapy. However, the majority of patients relapse following initial surgery and chemotherapy, highlighting the urgent need to develop new therapeutic strategies. In this Review, we outline the main therapeutic principles behind the management of newly diagnosed and recurrent epithelial ovarian cancer and discuss the current landscape of targeted and immune-based approaches. In this Review, Konstantinopoulos and Matulonis discuss recent clinical advances in the treatment of ovarian cancer and reflect on persisting challenges.
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
2
4
6
8
10
12
14
16
|
|
|
Frontiers in Oncology
16 publications, 6.56%
|
|
|
Discover Oncology
12 publications, 4.92%
|
|
|
Frontiers in Immunology
11 publications, 4.51%
|
|
|
Journal of Ovarian Research
11 publications, 4.51%
|
|
|
Phytomedicine
5 publications, 2.05%
|
|
|
Oncogene
4 publications, 1.64%
|
|
|
International Journal of Biological Macromolecules
4 publications, 1.64%
|
|
|
Pathology Research and Practice
4 publications, 1.64%
|
|
|
International Journal of Molecular Sciences
3 publications, 1.23%
|
|
|
Frontiers in Genetics
3 publications, 1.23%
|
|
|
Scientific Reports
3 publications, 1.23%
|
|
|
Frontiers in Pharmacology
3 publications, 1.23%
|
|
|
Journal of Translational Medicine
3 publications, 1.23%
|
|
|
International Immunopharmacology
3 publications, 1.23%
|
|
|
International Journal of Nanomedicine
3 publications, 1.23%
|
|
|
Advanced Science
3 publications, 1.23%
|
|
|
Cell Death and Disease
3 publications, 1.23%
|
|
|
Translational Cancer Research
3 publications, 1.23%
|
|
|
Critical Reviews in Oncology/Hematology
2 publications, 0.82%
|
|
|
Heliyon
2 publications, 0.82%
|
|
|
Pharmaceutics
2 publications, 0.82%
|
|
|
Cancer Cell International
2 publications, 0.82%
|
|
|
Translational Oncology
2 publications, 0.82%
|
|
|
Journal of Hematology and Oncology
2 publications, 0.82%
|
|
|
Oncology Reports
2 publications, 0.82%
|
|
|
BMC Medicine
2 publications, 0.82%
|
|
|
Biochemical Pharmacology
2 publications, 0.82%
|
|
|
BMC Cancer
2 publications, 0.82%
|
|
|
Genes and Diseases
2 publications, 0.82%
|
|
|
2
4
6
8
10
12
14
16
|
Publishers
|
10
20
30
40
50
60
70
|
|
|
Springer Nature
65 publications, 26.64%
|
|
|
Elsevier
64 publications, 26.23%
|
|
|
Frontiers Media S.A.
35 publications, 14.34%
|
|
|
Wiley
16 publications, 6.56%
|
|
|
MDPI
10 publications, 4.1%
|
|
|
Taylor & Francis
9 publications, 3.69%
|
|
|
Cold Spring Harbor Laboratory
8 publications, 3.28%
|
|
|
Spandidos Publications
5 publications, 2.05%
|
|
|
Research Square Platform LLC
3 publications, 1.23%
|
|
|
American Chemical Society (ACS)
3 publications, 1.23%
|
|
|
AME Publishing Company
3 publications, 1.23%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
3 publications, 1.23%
|
|
|
Public Library of Science (PLoS)
2 publications, 0.82%
|
|
|
SAGE
2 publications, 0.82%
|
|
|
IMR Press
2 publications, 0.82%
|
|
|
PeerJ
2 publications, 0.82%
|
|
|
Hans Publishers
1 publication, 0.41%
|
|
|
American Society of Clinical Oncology (ASCO)
1 publication, 0.41%
|
|
|
Portland Press
1 publication, 0.41%
|
|
|
Tsinghua University Press
1 publication, 0.41%
|
|
|
Begell House
1 publication, 0.41%
|
|
|
American Association for Cancer Research (AACR)
1 publication, 0.41%
|
|
|
Bentham Science Publishers Ltd.
1 publication, 0.41%
|
|
|
OAE Publishing Inc.
1 publication, 0.41%
|
|
|
Scientific Scholar
1 publication, 0.41%
|
|
|
Walter de Gruyter
1 publication, 0.41%
|
|
|
American Association for the Advancement of Science (AAAS)
1 publication, 0.41%
|
|
|
10
20
30
40
50
60
70
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
246
Total citations:
246
Citations from 2024:
234
(95.9%)
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
Konstantinopoulos P. A., Matulonis U. A. Clinical and translational advances in ovarian cancer therapy // Nature Cancer. 2023. Vol. 4. No. 9. pp. 1239-1257.
GOST all authors (up to 50)
Copy
Konstantinopoulos P. A., Matulonis U. A. Clinical and translational advances in ovarian cancer therapy // Nature Cancer. 2023. Vol. 4. No. 9. pp. 1239-1257.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1038/s43018-023-00617-9
UR - https://doi.org/10.1038/s43018-023-00617-9
TI - Clinical and translational advances in ovarian cancer therapy
T2 - Nature Cancer
AU - Konstantinopoulos, Panagiotis A.
AU - Matulonis, Ursula A
PY - 2023
DA - 2023/08/31
PB - Springer Nature
SP - 1239-1257
IS - 9
VL - 4
PMID - 37653142
SN - 2662-1347
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2023_Konstantinopoulos,
author = {Panagiotis A. Konstantinopoulos and Ursula A Matulonis},
title = {Clinical and translational advances in ovarian cancer therapy},
journal = {Nature Cancer},
year = {2023},
volume = {4},
publisher = {Springer Nature},
month = {aug},
url = {https://doi.org/10.1038/s43018-023-00617-9},
number = {9},
pages = {1239--1257},
doi = {10.1038/s43018-023-00617-9}
}
Cite this
MLA
Copy
Konstantinopoulos, Panagiotis A., and Ursula A Matulonis. “Clinical and translational advances in ovarian cancer therapy.” Nature Cancer, vol. 4, no. 9, Aug. 2023, pp. 1239-1257. https://doi.org/10.1038/s43018-023-00617-9.